IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

# Advancements In Chemotherapy: A Review Of Novel Drug Combinations For Cancer Treatment

**Lalit Kumar**

**Pharmacy assistant**

**Coventry University**

**ABSTRACT**

Chemotherapy has long been a cornerstone of cancer treatment, exerting its therapeutic effects primarily through the induction of cytotoxicity and cell cycle disruption. However, its efficacy is often compromised by dose-limiting toxicities, acquired resistance, and immunosuppressive effects within the tumor microenvironment. As a result, there is an urgent need for novel drug combinations that enhance anti-tumor activity while minimizing adverse effects. Recent advancements have demonstrated that integrating chemotherapy with immune checkpoint inhibitors, targeted therapies, and nanomedicine-based drug delivery systems can significantly improve treatment outcomes by modulating the immune response, increasing drug bioavailability, and overcoming tumor resistance mechanisms. Biomarker-driven strategies and CRISPR-mediated gene editing further represent promising avenues for optimizing chemotherapy regimens by structuring treatments to the molecular characteristics of individual tumors. This paper explores these cutting-edge developments, highlighting their implications for clinical practice and future research directions aimed at enhancing chemotherapy effectiveness.

**Keywords and phrases:** Chemotherapy, Drug Resistance, Immune Checkpoint Inhibitors, Targeted Therapy, Nanomedicine, Biomarker-driven Therapy, CRISPR, Tumor Microenvironment, Combination Therapy, Precision Oncology.

## INTRODUCTION

Chemotherapy has historically served as an important cancer treatment method, utilizing cytotoxic substances to attack and destroy rapidly dividing cancer cells. Chemotherapy primarily inhibits cancer cells from growing and dividing, disrupting their progression and ultimately leading to their destruction (Anand et al., 2022). However, traditional monotherapy approaches often encounter significant limitations, including the development of drug resistance and substantial toxicity, which can severely impact patient outcomes and quality of life (Marzieh et al., 2022). To address these challenges, combination chemotherapy has been developed to enhance therapeutic efficacy and limit adverse effects. Combination chemotherapy involves using multiple medications simultaneously to combat cancer, as each drug targets cancer cells at distinct stages of the cell cycle, thereby increasing the likelihood of eliminating all cancer cells (Eldridge et al., 2024). Combination therapy utilizes multiple agents with complementary mechanisms of action to enhance treatment response rates, postpone the development of resistance, and minimize toxicity through optimized dosing strategies.

In recent years, significant advancements have been made in chemotherapy drug combinations. Notably, the combination of doxorubicin and trabectedin has shown improved survival outcomes in patients with metastatic or unresectable leiomyosarcoma. The National Cancer Institute (2024) has shown that the combination of doxorubicin and trabectedin holds promise for treating leiomyosarcoma, a tumor arising in smooth muscle cells, typically found in the uterus, abdomen, and pelvis, though it can develop in other parts of the body. A phase 3 trial by Pautier et al. (2024) reported that patients receiving the doxorubicin-trabectedin combination had a median overall survival of 33 months (95% CI, 26–48), compared to 24 months (95% CI, 19–31) for those treated with doxorubicin alone, with an adjusted hazard ratio for death of 0.65 (95% CI, 0.44–0.95).

Similarly, in advanced breast cancer, a novel three-drug regimen has demonstrated a doubling in progression-free survival compared to existing treatments. The INAVO120 study, led by Professor Nicholas Turner from The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, highlights the promise of a new therapy combination in targeting PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which is a prevalent form of the disease (Institute of Cancer Research, 2024). Patients receiving the new combination therapy experienced a median progression-free survival of 13.2 months, whereas those on standard chemotherapy had 8.1 months.

These developments emphasize the potential of novel chemotherapy combinations to enhance treatment efficacy and patient outcomes. This paper aims to review recent advancements in chemotherapy drug combinations over the past five years, focusing on clinical trial results, underlying molecular mechanisms, and their impact on cancer treatment paradigms.

## SECTION 1: MECHANISMS OF ACTION IN CHEMOTHERAPY DRUGS

Chemotherapy drugs employ various mechanisms to target and destroy cancer cells, often by interfering with DNA replication, cell division, or cellular signaling pathways (Amjad et al., 2023). Understanding these mechanisms is crucial for optimizing combination therapies and improving treatment efficacy.

### Alkylating Agents

Alkylating agents, such as cyclophosphamide (Cytoxan), exert their cytotoxic effects by adding alkyl groups to DNA, leading to cross-linking of DNA strands. This disrupts DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing cancer cells. Despite their toxicity, DNA alkylating drugs, among the earliest and most commonly used anticancer agents, remain pivotal in chemotherapy by reacting with DNA and proteins to disrupt cell functions, leading to cell death or inhibited growth (Andrés et al., 2024). According to the FDA, cyclophosphamide is primarily indicated for treating malignant lymphomas at stages III and IV, as classified by the Ann Arbor staging system. This includes conditions such as Hodgkin and Non-Hodgkin lymphoma, lymphocytic lymphoma, small lymphocytic lymphoma, Burkitt lymphoma, and multiple myeloma (Ogino & Tadi, 2023). Cyclophosphamide is widely used in the treatment of lymphomas, breast cancer, and certain leukemias.

### Platinum-Based Compounds

Cisplatin, a platinum-based compound, induces DNA damage by forming intra- and interstrand cross-links, interfering with DNA repair mechanisms and leading to programmed cell death. Research by Zhang et al. (2022) highlights that Cisplatin enters tumor cells primarily through the copper transporter 1 (CTR1). Once inside, the lower intracellular chloride concentration facilitates the replacement of chloride ligands with water molecules, activating the platinum complex. This activated complex binds to DNA, forming intra- and inter-strand crosslinks, particularly at the N7 position of guanine. These crosslinks disrupt DNA replication and transcription, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells. Ranasinghe et al (2022) reported that In a 2014 report by the US National Institute of Cancer, cisplatin and other platinum-based anti-cancer drugs were prescribed to 10–20% of patients across various cancer types. Cisplatin, initially used for testicular and ovarian cancers, has become a cornerstone treatment for cancers such as bladder, lung, and head and neck cancers, often administered in combination regimens to improve effectiveness.

### Nitrosoureas

Nitrosoureas, such as carmustine (BCNU), are unique in their ability to cross the blood-brain barrier, making them effective in treating brain tumors like glioblastoma. According to Synapse Patsnap (2024), carmustine exerts its anticancer effects primarily by alkylating DNA at the O6 and N7 positions of guanine, leading to

interstrand and intrastrand cross-links that disrupt replication and transcription, ultimately triggering apoptosis. Additionally, it inhibits DNA repair mechanisms, induces oxidative stress through reactive oxygen species (ROS), interferes with RNA and protein synthesis, and may modulate the immune response, collectively enhancing its cytotoxic effects. The National Toxicology Program (2021) identified BCNU as being linked to the development of acute nonlymphocytic leukemia when used alongside other anticancer treatments. These agents not only alkylate DNA but also carbamylated proteins, impairing DNA repair and promoting apoptosis

**Antimetabolites**

Antimetabolites, including fluorouracil (5-FU), gemcitabine (Gemzar), and capecitabine (Xeloda), function by mimicking natural nucleotides, disrupting DNA and RNA synthesis. Fluorouracil inhibits thymidylate synthase, leading to a depletion of thymidine, a nucleotide essential for DNA replication. Casale & Patel (2025) noted that Fluorouracil, upon ingestion or topical application, is transported into cells, converted into fluorodeoxyuridine monophosphate (FdUMP), and inhibits deoxythymidine monophosphate (dTMP) production by forming complexes with thymidylate synthase, leading to nucleotide imbalance and endonuclease-facilitated double-stranded DNA breaks. Gemcitabine, on the other hand, induces "masked chain termination" by incorporating its nucleotide into the DNA strand, halting DNA polymerase activity, while also inhibiting DNA synthesis indirectly by reducing cellular dNTP pools through ribonucleotide reductase inhibition and triggering apoptotic cell death in human leukemia cells (CEM). Gemcitabine is incorporated into DNA, causing chain termination. While Capecitabine, an orally administered prodrug of 5-Fluorouracil (fluorouracil, 5-FU), shares the same cellular mechanism, 5-FU itself is an intravenously administered antimetabolite that functions as a pyrimidine analogue, disrupting DNA and RNA synthesis (Alzahrani et al., 2023)

**Anthracyclines**

Anthracyclines, such as doxorubicin (Adriamycin), epirubicin (Ellence), and mitoxantrone (Novantrone), exert their cytotoxic effects by inhibiting topoisomerase II, an enzyme essential for DNA unwinding during replication. Doxorubicin primarily acts by intercalating within DNA base pairs, leading to strand breakage and inhibition of DNA and RNA synthesis, while also inhibiting topoisomerase II to induce apoptosis (Johnson-Arbor & Dubey, 2023). Its interaction with iron generates free radicals that cause oxidative DNA damage, a process that can be limited by iron chelators like dexrazoxane. The DrugBank report (2024) explained that Epirubicin exerts its antimitotic and cytotoxic effects by intercalating into DNA, disrupting nucleic acid and protein synthesis, and stabilizing the DNA-topoisomerase II complex to inhibit DNA religation. It disrupts DNA replication and transcription by inhibiting DNA helicase activity. Mitoxantrone intercalates into DNA through hydrogen bonding, causing crosslinks and strand breaks while also inhibiting RNA synthesis and topoisomerase II activity, which disrupts DNA repair (National Center for Biotechnology Information, 2025). Its cytocidal effects extend to both proliferating and nonproliferating cells, indicating a lack of cell cycle phase specificity.

This leads to DNA strand breaks and apoptosis. Additionally, anthracyclines generate free radicals, further contributing to their antitumor activity.

**Mitotic Inhibitors**

Mitotic inhibitors, including vinorelbine (Navelbine), docetaxel (Taxotere), and ixabepilone (Ixempra), disrupt microtubule function, preventing proper chromosome segregation during mitosis. Vinorelbine, a vinca alkaloid available in both intravenous and oral formulations, exerts cytotoxic effects by disrupting mitotic spindle formation and preventing cell division. It is an effective treatment for metastatic breast cancer (MBC), either as a single agent or in combination, with its oral formulation (Navelbine® Oral) recognized as an economically viable option due to its low toxicity profile and good tumor control (Pierre et al., 2020). Docetaxel, a second-generation taxane derived from paclitaxel, binds to β-tubulin, stabilizing microtubules and inhibiting proper mitotic spindle formation, which arrests the cell cycle at the G2/M phase. Additionally, it downregulates the anti-apoptotic gene BCL2, enhancing apoptosis in cancer cells (Nicole & Anup, 2024). Ixabepilone, a semi-synthetic analog of epothilone B with microtubule inhibitory activity, is approved for use in combination with capecitabine for metastatic or locally advanced breast cancer (BC) following anthracycline and taxane failure. It is also approved as monotherapy for patients whose disease has progressed despite prior treatment with an anthracycline, a taxane, and capecitabine, offering potential benefits in overcoming resistance mechanisms (Ibrahim, 2021). Through halting cell division, these agents induce apoptosis, with docetaxel demonstrating efficacy in breast, prostate, and lung cancers.

**Other Chemotherapeutic Agents**

Certain agents, such as all-trans-retinoic acid (ATRA) and arsenic trioxide, have specific targeted mechanisms in cancer therapy. ATRA promotes the transcriptional activation of differentiation-related genes and exerts anti-APL effects by regulating autophagy through mTOR inhibition (Liang et al., 2021). It induces differentiation in acute promyelocytic leukemia (APL) cells and reduces the malignant phenotype. The mechanism of action of arsenic trioxide is not fully understood, but it induces apoptosis in NB4 human promyelocytic leukemia cells by causing morphological changes and DNA fragmentation, while also degrading the PML/RAR-alpha fusion protein (National Center for Biotechnology Information, 2025). It induces apoptosis through reactive oxygen species generation and mitochondrial damage. These targeted therapies have transformed the treatment for APL.

**SECTION 2: CHALLENGES IN CHEMOTHERAPY AND THE NEED FOR DRUG COMBINATIONS**

Chemotherapy remains a fundamental component of cancer treatment, but its effectiveness is often challenged by various factors, necessitating the use of drug combinations to improve therapeutic outcomes. One major hurdle is drug resistance mechanisms, such as the overexpression of efflux transporters like P-glycoprotein, which actively pump chemotherapeutic agents out of cancer cells, reducing intracellular drug concentrations

and limiting efficacy. According to Tian et al. (2023), P-gp overexpression diminishes intracellular drug concentrations and cytotoxicity by expelling cisplatin, paclitaxel, 5-fluorouracil (5-FU), doxorubicin, and other chemotherapeutic agents through its efflux pump function, thereby reducing their proliferation-inhibiting effects on tumor cells. The development of P-gp inhibitors is considered a promising strategy for reversing this form of multidrug resistance; however, despite extensive research over the past few decades, no effective P-gp inhibitors have reached the market due to their toxic effects (Mora & Novič, 2022). Also, enhanced DNA repair mechanisms allow cancer cells to counteract the cytotoxic effects of DNA-damaging agents, further contributing to resistance. Li et al. (2021) suggested that, as primary anticancer therapies, ionizing radiation and chemotherapeutic agents induce cell death by causing direct or indirect DNA damage, and dysregulation of the DNA damage response can lead to either hypersensitivity or resistance to genotoxic agents, making the targeting of DNA repair pathways a potential strategy to enhance tumor sensitivity to cancer treatments.

Toxicity and side effects present another significant limitation, as many chemotherapeutic agents cause severe adverse reactions, including myelosuppression, neurotoxicity, and organ damage, often leading to dose reductions or treatment discontinuation. Amjad et al. (2023) emphasized the importance of recognizing strong CYP enzyme inducers, such as phenobarbital and phenytoin, and inhibitors, like grapefruit juice and ketoconazole, as they can alter chemotherapy drug levels, potentially reducing efficacy or increasing toxicity. Also, interpatient variability due to genetic and metabolic differences affects drug metabolism, distribution, and elimination, resulting in unpredictable treatment responses and varying degrees of toxicity among patients. Pamuła-Piłat et al. (2020) analyzed 33 germline polymorphisms in the 3′UTRs of ADME genes in 305 breast cancer patients treated with the FAC regimen, identifying associations between specific genetic variants and clinical factors with overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and treatment failure-free survival (TFFS). Their findings suggest that the accumulation of certain genetic polymorphisms and clinical factors, such as tumor size, nodal involvement, and preexisting metastases, contributes to poor survival prognosis and diminished treatment response.

These challenges emphasize the importance of combination therapies, which aim to overcome resistance, reduce toxicity through dose adjustments, and enhance patient outcomes by simultaneously targeting multiple pathways. The rationale for combination therapy is to employ medications with different mechanisms of action to minimize the development of resistant cancer cells while allowing each drug to be administered at its optimal dose without causing intolerable side effects (Gale, 2024).

## SECTION 3: RECENT ADVANCEMENTS IN CHEMOTHERAPY DRUG COMBINATIONS

### 3.1 Platinum-Based Combinations

Platinum-based chemotherapy is an integral part of cancer treatment, particularly in solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, and breast cancer. The combination of platinum drugs with agents that have distinct anticancer mechanisms, particularly checkpoint inhibitors, has emerged as a key

strategy to overcome drug resistance, enhance therapeutic efficacy, and reduce severe toxic effects in chemotherapy (Yu et al., 2020). Cisplatin and carboplatin, the most commonly used platinum compounds, function by forming DNA cross-links that disrupt replication and transcription, ultimately triggering apoptosis in rapidly dividing cancer cells. However, their clinical effectiveness is often enhanced when combined with other chemotherapeutic agents that act through complementary mechanisms.

**Cisplatin + Gemcitabine for Non-Small Cell Lung Cancer (NSCLC)**

Cisplatin exerts non-cell cycle-specific cytotoxicity by covalently binding to purine bases, guanine and adenine, leading to intra-strand and inter-strand DNA crosslinks that cause strand breaks. While DNA repair mechanisms attempt to mitigate this damage, persistent lesions in DNA, RNA, and proteins often drive cells toward apoptotic or non-apoptotic cell death, making cisplatin particularly effective against rapidly proliferating malignant tumors (Gold & Raja, 2023). When combined with gemcitabine, a pyrimidine analog that inhibits DNA synthesis, the dual mechanism enhances tumor cell death by simultaneously disrupting DNA integrity and nucleotide metabolism. Gemcitabine, a β-isomer and nucleoside analogue, exhibits antiviral properties and low toxicity, making it an effective anticancer agent by incorporating into DNA and triggering apoptosis. The cisplatin-gemcitabine combination has been widely used in NSCLC due to its superior response rates compared to cisplatin alone (Minerva et al., 2023).

Wang et al. (2022) compared gemcitabine/carboplatin with paclitaxel/cisplatin and found that while both regimens provide similar therapeutic efficacy, the gemcitabine/carboplatin combination is associated with higher toxicity levels. Clinical trials have demonstrated that cisplatin-gemcitabine regimens improve progression-free survival (PFS), making them a standard first-line treatment in advanced NSCLC. Choi et al. (2024) reported that a regimen of gemcitabine, cisplatin, and nab-paclitaxel (GPA) improved PFS in patients with advanced biliary tract cancer (aBTC) compared to the gemcitabine-cisplatin (GP) regimen but did not yield a significant overall survival (OS) benefit after adjusting for confounding factors. Meanwhile, Scagliotti et al. (2023) demonstrated that in advanced NSCLC, the cisplatin/pemetrexed regimen offers comparable efficacy to cisplatin/gemcitabine while providing better tolerability and more convenient administration. Notably, this was the first prospective phase III study in NSCLC to reveal survival differences based on histologic subtype.

**Carboplatin + Paclitaxel for Ovarian and Breast Cancer**

Carboplatin, a second-generation platinum agent with reduced nephrotoxicity compared to cisplatin, induces DNA adduct formation, leading to cell cycle arrest and apoptosis. It is widely used to treat ovarian, head and neck, and lung cancers, with a low incidence of transient liver enzyme elevations and rare cases of clinically apparent liver injury (LiverTox, 2020). When combined with paclitaxel, a microtubule-stabilizing agent that disrupts mitotic spindle disassembly (Awosika et al., 2023), the synergy between DNA damage and mitotic arrest enhances cytotoxicity. Carboplatin-paclitaxel is the gold-standard chemotherapy regimen for ovarian cancer, improving response rates and survival in both early and advanced disease. Robert et al. (2023) found

that in advanced ovarian cancer, carboplatin plus paclitaxel was less toxic, easier to administer, and not inferior to cisplatin plus paclitaxel. Wang et al. (2021) reported that albumin-bound paclitaxel combined with carboplatin (Nab-TC) as a neoadjuvant chemotherapy (NAC) regimen for advanced primary epithelial ovarian cancer was non-inferior to the traditional solvent-based paclitaxel-carboplatin (TC) regimen, offering lower toxicity, longer progression-free survival (PFS), and improved quality of life. However, in a randomized clinical trial of 120 older patients with ovarian cancer, single-agent carboplatin was less effective than the standard every-3-weeks carboplatin-paclitaxel regimen, leading to significantly worse PFS and overall survival, prompting early trial termination (Falandry et al., 2021). In breast cancer, particularly triple-negative subtypes, this combination has demonstrated strong efficacy in neoadjuvant and metastatic settings, with higher pathologic complete response (pCR) rates than non-platinum regimens. Yu et al. (2020) conducted a phase 3 clinical trial across nine cancer centers in China with 647 patients, finding that after a median follow-up of 62 months, the 5-year disease-free survival rate was significantly higher in the paclitaxel-carboplatin (PCb) group compared to the cyclophosphamide, epirubicin, and fluorouracil followed by docetaxel (CEF-T) group, supporting PCb as an alternative adjuvant chemotherapy for operable triple-negative breast cancer. Bianchi et al. (2023) compared carboplatin-paclitaxel (CP) and carboplatin-gemcitabine (CG) in advanced triple-negative breast cancer (TNBC), concluding that both were effective and well-tolerated, though CG showed greater efficacy in taxane-pretreated patients despite its higher toxicity profile.

### 3.2 Anthracycline-Based Combinations

Anthracyclines, such as doxorubicin and epirubicin, are widely used in chemotherapy due to their potent anti-tumor activity. They work primarily by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and apoptosis (Hansheng et al., 2024). However, their clinical utility is often enhanced when combined with other agents, particularly in breast cancer treatment.

**Doxorubicin + Cyclophosphamide (AC Regimen) for Breast Cancer**

The doxorubicin and cyclophosphamide (AC) regimen is a standard chemotherapy protocol for early-stage and metastatic breast cancer. Doxorubicin, an anthracycline, induces oxidative DNA damage via free radical generation (Kong et al., 2024), while cyclophosphamide, an alkylating agent, disrupts tumor cell replication by forming DNA cross-links (Olowe et al., 2024). Clinical studies have shown that the AC regimen significantly improves disease-free survival (DFS) and overall survival (OS) compared to monotherapy. Ling-Ming et al. (2024) conducted a multicenter, phase II randomized non-inferiority trial—the first prospective two-arm randomized controlled study—to compare pegylated liposomal doxorubicin (PLD)-based and epirubicin-based adjuvant chemotherapy in stage I-II HER2-negative breast cancer. The study found no significant differences in 5-year DFS and OS rates between the regimens, but the PLD-based regimen had fewer grade 3–4 adverse events (AEs) and a trend toward improved quality of life (QoL), suggesting its potential as a new standard treatment. Additionally, Dewidar et al. (2024) reported that combining pitavastatin or simvastatin with

doxorubicin and cyclophosphamide may enhance apoptosis in breast cancer cells by upregulating the Bax/Bcl2 pathway, highlighting a potential therapeutic advancement in breast cancer treatment.

**Epirubicin + 5-Fluorouracil + Cyclophosphamide (FEC Regimen) in Metastatic Breast Cancer**

The FEC regimen, which combines epirubicin, 5-fluorouracil (5-FU), and cyclophosphamide, is a widely used anthracycline-based chemotherapy in metastatic breast cancer. Epirubicin, a structural analog of doxorubicin, offers similar efficacy with reduced cardiotoxicity (University of Pennsylvania, 2020). As an anthracycline, it disrupts DNA synthesis and essential cellular processes, inhibiting the replication of rapidly dividing cells. 5-FU exerts cytotoxic effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA, impairing normal cellular functions (Sethy et al., 2021). Cyclophosphamide, a nitrogen mustard alkylating agent, metabolizes into its active form to induce DNA crosslinking, thereby inhibiting protein synthesis and cell division (Mari & Prasanna, 2023). The synergy of these agents has led to improved response rates and prolonged survival in patients with metastatic breast cancer. Although primarily used in metastatic settings, the FEC regimen has also been explored in neoadjuvant therapy. A pilot trial by Wu et al. (2021) comparing neoadjuvant everolimus plus letrozole with FEC in ER-positive, HER2-negative breast cancer found that everolimus plus letrozole may offer a favorable ultrasound response rate, lower toxicity, and potential antitumoral immunity benefits in postmenopausal patients. Additionally, a phase II trial by Kin et al. (2020) evaluating the sequence of nab-paclitaxel followed by FEC in neoadjuvant chemotherapy for resectable breast cancer reported a 24% overall pathologic complete response (pCR) rate, with a notably higher 55% pCR rate in HER2-positive patients, suggesting the effectiveness and tolerability of this approach, particularly when combined with trastuzumab every three weeks.

**3.3 Targeted and Cytotoxic Drug Combinations**

Recent advancements in chemotherapy have led to the integration of targeted therapies with traditional cytotoxic agents to enhance efficacy while potentially reducing toxicity. These combinations are particularly valuable in cases where single-agent chemotherapy fails due to resistance mechanisms.

Arsenic Trioxide + All-Trans Retinoic Acid (ATRA) for Acute Promyelocytic Leukemia (APL)

The combination of arsenic trioxide and ATRA has transformed the treatment of acute promyelocytic leukemia (APL) (Cicconi et al., 2024). ATRA acts as a differentiating agent by promoting the degradation of the PML-RARα fusion protein, thereby facilitating normal myeloid differentiation (Orfali et al., 2020). Arsenic trioxide complements this process by inducing apoptosis through oxidative stress and further degrading PML-RARα (Xie et al., 2024). Clinical trials have demonstrated that the ATRA-arsenic trioxide regimen achieves higher complete remission rates than conventional chemotherapy, with fewer long-term toxicities (Wang et al., 2022). Gaurav et al. (2020) reported that high-risk APL patients face poorer outcomes than low-risk cases, primarily due to an increased risk of early mortality from hemorrhage. While many regimens include prolonged maintenance therapy, its role remains uncertain in the era of ATRA and arsenic trioxide. Harinder et al. (2023)

evaluated a fully oral arsenic trioxide (oral-ATO) solution (Arsenol®) combined with ATRA and ascorbic acid (AAA regimen) in a risk-adapted, chemotherapy-minimized approach for newly diagnosed APL. Their findings confirmed its efficacy across all risk groups and age ranges, though early mortality remains a barrier to achieving a universal cure.

**Methotrexate + Vinorelbine for Lung Cancer**

Methotrexate, a folate antagonist, inhibits dihydrofolate reductase, preventing nucleotide synthesis and leading to cell cycle arrest. According to Hanoodi and Mittal (2024), methotrexate is an effective antifolate antimetabolite used in cancer treatment, entering cells through reduced folate carriers, forming methotrexate-polyglutamate, and inhibiting key enzymes—dihydrofolate reductase, purine synthase, and thymidylate synthase—thereby disrupting nucleotide synthesis and DNA production. Vinorelbine, a vinca alkaloid, disrupts microtubule formation, leading to mitotic arrest (Pierre et al., 2020). The combination of these agents has shown efficacy in non-small cell lung cancer (NSCLC), particularly in elderly or frail patients who cannot tolerate platinum-based regimens (Vergnenegre et al., 2023). A Phase II trial conducted by the Cancer Institute and Hospital (2025) is evaluating the efficacy and safety of concurrent chemoradiotherapy with oral vinorelbine in patients with unresectable stage III NSCLC who previously received neoadjuvant chemo-immunotherapy. The study, which began in March 2023 and is expected to conclude by June 2026, aims to establish an effective treatment regimen by combining oral vinorelbine with radiotherapy followed by immune-maintenance therapy. The primary endpoint is the objective response rate, while secondary endpoints include disease control rate, progression-free survival, compliance, and safety. The VinMetAtezo trial, a multicenter Phase II study, assessed the safety and efficacy of metronomic oral vinorelbine with atezolizumab as a second-line treatment for stage IV NSCLC, reporting a 4-month progression-free survival (PFS) rate of 32%, a median PFS of 2.2 months, and a median overall survival of 7.9 months. The overall response rate was 11%, and the disease control rate at 4 months was 32% (Vergnenegre et al., 2023).

**3.4 Immunotherapy and Chemotherapy Synergies**

Immune checkpoint inhibitors have revolutionized cancer treatment, and their combination with chemotherapy not only enhances anti-tumor immune responses but also restores immunosurveillance, a critical mechanism previously overlooked in preclinical and clinical research (Zhang et all., 2022).

**Checkpoint Inhibitors (e.g., Pembrolizumab) + Traditional Chemotherapy**

Pembrolizumab, a PD-1 checkpoint inhibitor, enhances the immune system’s ability to recognize and attack tumor cells. Initially granted FDA accelerated approval for refractory advanced melanoma in September 2014, pembrolizumab has since been approved for multiple oncologic indications, with ongoing clinical development for additional uses (Flynn et al., 2023). When combined with chemotherapy, it not only suppresses tumor growth but also facilitates antigen presentation, making tumor cells more susceptible to immune-mediated destruction.

While chemotherapy and immunotherapy can have antagonistic effects, Sordo-Bahamonde et al. (2023) suggest that certain chemotherapeutic agents, including those used for autoimmune diseases or transplant rejection, may also stimulate immune responses under specific conditions. The rationale for combining chemotherapy with immunotherapy lies in chemotherapy's ability to reduce tumor burden and suppress immunosuppressive factors, thereby enhancing antitumor immunity, particularly in "cold" tumors with low T cell infiltration. In non-small cell lung cancer (NSCLC), pembrolizumab combined with platinum-based chemotherapy has demonstrated significantly improved overall survival compared to chemotherapy alone. Hossein et al. (2020) found that pembrolizumab plus chemotherapy improved response rates and survival outcomes with manageable safety in PD-L1–negative advanced/metastatic NSCLC, leading to its adoption as a standard first-line therapy for advanced NSCLC, regardless of PD-L1 expression.

**Role of Chemotherapy in Enhancing the Immune Response to Cancer**

Chemotherapy can enhance anti-tumor immunity by inducing immunogenic cell death, which increases the exposure of tumor-associated antigens to the immune system (Calvillo-Rodríguez et al., 2023). Additionally, certain chemotherapeutic agents deplete immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells, thereby enhancing immune checkpoint blockade efficacy. Haist et al. (2021) observed that the accumulation of immunosuppressive cell populations within the tumor microenvironment (TME), including MDSC, TAM, and Treg, contributes to immune resistance by inhibiting T cell activation and effector function. Studies have revealed that these inhibitory mechanisms involve soluble immunomodulatory mediators and receptor interactions, which are essential for the crosstalk between MDSC and Treg, highlighting the importance of cell-cell contacts in establishing their suppressive properties. Mukherjee et al. (2023) highlight that chemotherapeutic agents such as cisplatin, doxorubicin, and azacytidine possess both cytotoxic and immunoregulatory properties, with studies indicating direct and indirect interactions between these agents and the immune system. Chemotherapy-induced antigen exposure facilitates dendritic cell activation and pro-inflammatory cytokine release, ultimately enhancing T cell priming and adaptive immune responses. Sheykhhasan et al. (2025) highlight that Dendritic cells (DCs), essential for antigen presentation in cancer immunotherapy, show promise in DC-based vaccines despite limited success, with efficacy enhanced by improving antigen loading, overcoming immune suppression, and combining with immune checkpoint inhibitors and adjuvants. However, some chemotherapeutic regimens may also cause lymphocyte depletion and transient immunosuppression, highlighting the need for precise dosing and scheduling to maximize synergy with immunotherapy (Truong et al., 2021). These synergistic effects emphasize the rationale for combining chemotherapy with immunotherapy in cancer treatment.

## SECTION 4: FUTURE DIRECTIONS IN CHEMOTHERAPY DRUG Personalized Oncology & Biomarker-Driven Therapy

Personalized oncology tailors cancer treatment to an individual's genetic and molecular tumor profile, enabling more effective and less toxic therapies by sequencing the tumor and identifying unique genetic alterations for precise, patient-specific outcomes (Sava, 2025). Biomarker-driven therapy identifies molecular markers that predict treatment response, ensuring that chemotherapy is combined with targeted agents to maximize efficacy. Advances in next-generation sequencing (NGS) and liquid biopsy have enabled real-time monitoring of tumor evolution, allowing oncologists to adjust chemotherapy regimens dynamically (Zalis et al., 2024). An example is BRCA-mutated breast and ovarian cancers which respond better to platinum-based chemotherapy and PARP inhibitors, while microsatellite instability-high (MSI-H) tumors exhibit increased sensitivity to immune checkpoint inhibitors combined with chemotherapy (Valenza et al., 2023; Asiri et al., 2023; Alyssa, 2023). Additionally, researchers are investigating minimal residual disease (MRD) to predict relapse and guide chemotherapy duration, improving long-term patient outcomes (Li, 2022). However, challenges remain in ensuring broad access to biomarker testing and integrating these strategies into routine clinical practice.

### Nanomedicine & Targeted Drug Delivery Systems

Nanomedicine offers a transformative approach to chemotherapy by improving drug solubility, stability, and tumor-targeting capabilities. Nanoparticles, including liposomes, polymeric micelles, and gold-based carriers, can encapsulate chemotherapeutic agents, reducing systemic toxicity and enhancing drug accumulation in tumors through the enhanced permeability and retention (EPR) effect (Ghazal et al., 2024). One successful example is pegylated liposomal doxorubicin (Doxil), which prolongs circulation time and reduces cardiac toxicity compared to conventional doxorubicin (Alberto et al., 2025). Additionally, ligand-targeted nanoparticles, such as folic acid-conjugated nanocarriers, enhance selective drug delivery to cancer cells expressing folate receptors, improving treatment specificity (Yan et al., 2024). Researchers are also exploring stimuli-responsive nanocarriers that release chemotherapy in response to pH, enzymes, or heat, increasing precision and reducing off-target effects (Pramod et al., 2023). While nanomedicine shows promise, challenges such as large-scale production, cost, and regulatory approval hinder widespread adoption (Emmanuel, 2025).

### Gene Editing (CRISPR) in Combination with Chemotherapy

CRISPR-Cas9 technology is improving cancer treatment by enabling precise genome modifications that enhance chemotherapy efficacy. Researchers are using CRISPR to disrupt genes associated with chemotherapy resistance, such as MDR1, which encodes P-glycoprotein, a key efflux pump responsible for drug resistance in many cancers (Vaghari-Tabari et al., 2022). In preclinical studies, CRISPR has been employed to knock out DNA damage repair genes in tumor cells, sensitizing them to platinum-based chemotherapy (Issa et al., 2024). Additionally, CRISPR-engineered T cells (CAR-T) are being explored to enhance immunotherapy responses when combined with chemotherapy, particularly in hematologic malignancies (Wellhausen et al., 2021).

However, ethical concerns, off-target effects, and the need for precise delivery mechanisms remain significant barriers to clinical translation. Future research should aims to refine CRISPR delivery methods, such as using lipid nanoparticles or viral vectors, to enhance safety and efficiency in combination therapies.

## CONCLUSION

Recent advancements in chemotherapy drug combinations proffers their potential to revolutionize cancer treatment by enhancing therapeutic efficacy while minimizing toxicity. Checkpoint inhibitors such as pembrolizumab, when combined with traditional chemotherapy, have demonstrated improved survival rates across multiple cancer types by augmenting immune-mediated tumor destruction. Chemotherapy's role in immune modulation, particularly through immunogenic cell death and depletion of immunosuppressive cell populations, has shifted its perception from merely a cytotoxic intervention to a crucial facilitator of anti-tumor immunity. The integration of biomarker-driven therapies, nanomedicine, and CRISPR-based gene editing further exemplifies a transition towards precision oncology, where treatment regimens are tailored to the molecular landscape of individual tumors.

Emerging clinical data indicate that rationally designed drug combinations can improve overall and progression-free survival and enhance patients' quality of life by reducing systemic toxicity and limiting resistance mechanisms. For instance, PARP inhibitors have shown remarkable efficacy in BRCA-mutated cancers, while platinum-based regimens combined with immune checkpoint inhibitors have redefined first-line treatment protocols for non-small cell lung cancer (NSCLC). Nanoparticle-based drug delivery systems improve drug bioavailability, limit off-target effects, and enable the controlled release of chemotherapeutic agents, addressing key challenges such as dose-limiting toxicities. However, despite these advancements, disparities in treatment accessibility and long-term adverse effects remain critical concerns that require systematic evaluation.

The future of chemotherapy lies in its strategic integration with emerging biotechnologies. Next-generation sequencing and artificial intelligence-driven predictive models hold promise for refining patient selection, ensuring that combination therapies are administered to those most likely to benefit. Further exploration of epigenetic regulators and tumor microenvironment reprogramming could unlock new synergies between chemotherapy and immunotherapy. Additionally, the application of gene-editing tools such as CRISPR to sensitize tumor cells to chemotherapy while sparing normal tissue represents a paradigm shift in oncologic precision medicine. Addressing tumor heterogeneity, overcoming acquired resistance, and optimizing combination sequencing will be pivotal in shaping the next era of cancer therapeutics.

**REFERENCE**


1. Alberto A Gabizon, Shira Gabizon-Peretz, Shadan Modaresahmadi, Ninh M La-Beck. (2025). Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. Volume 4, Issue 1. https://bmjoncology.bmj.com/content/4/1/e000573
2. Alyssa Walton. (2023). What is platinum-based chemotherapy? https://www.medicalnewstoday.com/articles/platinum-based-chemotherapy
3. Alzahrani, S.M., Al Doghaither, H.A., Al-Ghafari, A.B., & Pushparaj, P.N. (2023). 5-Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review). Oncology Reports, 50, 175. https://doi.org/10.3892/or.2023.8612
4. Amjad MT, Chidharla A, Kasi A. (2023). Cancer Chemotherapy. [Updated 2023 Feb 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564367/#
5. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK, Dewanjee S, Vallamkondu J, Pérez de la Lastra JM. (2022). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022 Mar 18;10(4):1367-1401. doi: 10.1016/j.gendis.2022.02.007. Erratum in: Genes Dis. 2024 Jan 20;11(4):101211. doi: 10.1016/j.gendis.2024.101211. PMID: 37397557; PMCID: PMC10310991.
6. Andrés, C. M. C., Pérez de la Lastra, J. M., Munguira, E. B., Andrés Juan, C., & Pérez-Lebeña, E. (2024). Dual-Action Therapeutics: DNA Alkylation and Antimicrobial Peptides for Cancer Therapy. Cancers, 16(18), 3123. https://doi.org/10.3390/cancers16183123
7. Asiri MS, Dabaliz A, Almutairi M, Almahbub A, Alharbi M, Almeman S, AlShieban S, Alotaibi T, Algarni M. (2023). Complete Pathological Response to Platinum-Based Neoadjuvant Chemotherapy in BRCA2-Associated Locally Advanced Pancreatic Cancer: A Case Report and Literature Review. Cureus. 2023 Aug 10;15(8):e43261. doi: 10.7759/cureus.43261. PMID: 37692681; PMCID: PMC10492221.
8. Awosika AO, Farrar MC, Jacobs TF. Paclitaxel. [Updated 2023 Nov 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536917/
9. Cancer Institute and Hospital (2025). Study of oral vinorelbine with chemoradiotherapy in lung cancer (NCT06540950). MedPath. https://trial.medpath.com/clinical-trial/c9f00396fd8424c9/nct06540950-study-oral-vinorelbine-chemoradiotherapy-lung-cancer
10. Carmine Valenza, Dario Trapani, Sara Gandini, Caterina Sposetti, Luca Boscolo Bielo, Antonio Marra, Tommaso Giarratano, Diletta Favero, Laura Cortesi, Luca Moscetti, Mirco Pistelli, Rossana Berardi, Alberto Zambelli, Matteo Lambertini, Lucia Del Mastro, Valentina Guarneri, Claudio Vernieri, Giuseppe Curigliano. (2023). Platinum-based chemotherapy and PARP inhibitors for patients with a

germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. European Journal of Cancer, Volume 190, 112944, ISSN 0959-8049. https://doi.org/10.1016/j.ejca.2023.112944.

11. Casale J, Patel P. (2025). Fluorouracil. [Updated 2024 Feb 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549808/#
12. Chinmayee Sethy, Chanakya Nath Kundu. (2021). 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implication of DNA repair inhibition. Biomedicine & Pharmacotherapy, Volume 137, 111285, ISSN 0753-3322. https://doi.org/10.1016/j.biopha.2021.111285.
13. Choi JH, Park H, Park JK, Lee JK, Lee KT, Lee KH. (2024). Prolonged progression-free survival achieved by gemcitabine, cisplatin, and albumin-bound paclitaxel for the treatment of advanced biliary tract cancers. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359231225045
14. Cicconi L, Bisegna M, Gurnari C, Fanciullo D, Piciocchi A, Marsili G, Minotti C, Scalzulli E, Mandelli B, Guarnera L, Perrone S, Ortu La Barbera E, Mecarocci S, Biagi A, Cenfra N, Corbingi A, Scerpa MC, Venditti A, Martelli M, Voso MT, Breccia M, Pulsoni A. (2024). Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications. Br J Haematol. 2024 Nov;205(5):1727-1733. doi: 10.1111/bjh.19759. Epub 2024 Sep 14. PMID: 39275865.
15. Dewidar, S.A., Hamdy, O., Soliman, M.M. et al. (2024). Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells. Med Oncol 41, 7 (2024). https://doi.org/10.1007/s12032-023-02248-7
16. DrugBank Online. (2024). Epirubicin: Uses, interactions, mechanism of action. Retrieved from https://go.drugbank.com/drugs/DB00445
17. Falandry C, Rousseau F, Mouret-Reynier M, et al. (2021). Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial. JAMA Oncol.2021;7(6):853–861. doi:10.1001/jamaoncol.2021.0696
18. Flynn JP, Gerriets V. Pembrolizumab. [Updated 2023 Jun 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546616/
19. Gaurav Shah, Fady M. Mikhail, Kimo Bachiasvili, Pankit Vachhani, Harry P. Erba, Nikolaos Papadantonakis. (2020). Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series. Hematology/Oncology and Stem Cell Therapy, Volume 13, Issue 3, Pages 143-146, ISSN 1658-3876. https://doi.org/10.1016/j.hemonc.2019.08.006.

20. Giorgio Vittorio Scagliotti et al. (2023). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. JCO 41, 2458-2466(2023). DOI:10.1200/JCO.22.02544
21. Gold JM, Raja A. Cisplatin. [Updated 2023 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547695/
22. Haist M, Stege H, Grabbe S, Bros M. (2021). The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. Cancers (Basel). 2021 Jan 8;13(2):210. doi: 10.3390/cancers13020210. PMID: 33430105; PMCID: PMC7827203.
23. Hanoodi M, Mittal M. Methotrexate. [Updated 2024 Dec 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556114/
24. Hansheng Li, Meilun Wang, Yan Huang. (2024). Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective. Biomedicine & Pharmacotherapy, Volume 179, 117312, ISSN 0753-3322. https://doi.org/10.1016/j.biopha.2024.117312.
25. Harinder Gill, Rita Yim, Lynn Chin, Paul Lee, Vivian Li,Lester Au, Garret Man Kit Leung, Ka Leung Daniel Cheuk,Shau-Yin Ha, Chi Kong Li, Melissa Ooi, Wee-Joo Chng,Patrick Chu, Cyrus Kumana, Yok Lam Kwong. (2023). An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial. https://doi.org/10.1182/blood-2023-179644
26. Hossein Borghaei DO, Corey J. Langer MD, Luis Paz-Ares MD, Delvys Rodríguez-Abreu MD, Balazs Halmos MD, Marina C. Garassino MD, Baerin Houghton MD, Takayasu Kurata MD, Ying Cheng MD, Jianxin Lin MS, M. Catherine Pietanza MD, Bilal Piperdi MD, Shirish M. Gadgeel MD. (2020). Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. https://doi.org/10.1002/cncr.33142
27. Huma Ghazal, Aimen Waqar, Faiza Yaseen, Muhammad Shahid, Mahnoor Sultana, Mehlayl Tariq, Muhammad Kamran Bashir, Hira Tahseen, Tehreem Raza, Farooq Ahmad. (2024). Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment. Next Materials, Volume 2, 100128, ISSN 2949-8228. https://doi.org/10.1016/j.nxmate.2024.100128.
28. Institute of Cancer Research. (2024). Powerful new therapy doubles progression-free survival in advanced breast cancer. Retrieved from https://www.icr.ac.uk/about-us/icr-news/detail/powerful-new-therapy-doubles-progression-free-survival-in-advanced-breast-cancer
29. Issa II, Due H, Brøndum RF, Veeravakaran V, Haraldsdóttir H, Sylvester C, Brogaard A, Dhanjal S, Schmierer B, Dybkær K. (2024). CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and BTKas Essential for Cisplatin Response in Diffuse Large B-Cell Lymphoma. Cancers

(Basel). 2024 Jul 2;16(13):2437. doi: 10.3390/cancers16132437. PMID: 39001501; PMCID: PMC11240649.

30. Johnson-Arbor K, Dubey R. (2023). Doxorubicin. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459232/
31. Jordyn Sava. (2025). Evolution of Personalized Cancer Care With Molecular Profiling. https://www.targetedonc.com/view/evolution-of-personalized-cancer-care-with-molecular-profiling#
32. Kenny Misael Calvillo-Rodríguez, Helen Yarimet Lorenzo-Anota, Cristina Rodríguez-Padilla, Ana Carolina Martínez-Torres, Daniel Scott-Algara. (2023). Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system. Front. Immunol. , 23, Sec. Cancer Immunity and Immunotherapy, Volume 14 - 2023 | https://doi.org/10.3389/fimmu.2023.1294434
33. Kin T, Ohtani S, Maeda R, Ueno A, Fujihara M, Takamatsu Y, Kajiwara Y, Ito M, Kawasaki K, Abe K, Sakata Y, Hiraki K. (2020). Nab-Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide in Neoadjuvant Chemotherapy for Resectable Breast Cancer: A Phase II Trial. World J Oncol. 2020 Oct;11(5):197-203. doi: 10.14740/wjon1333. Epub 2020 Oct 15. PMID: 33117463; PMCID: PMC7575276.
34. Kong CY, Guo Z, Song P, Zhang X, Yuan YP, Teng T, Yan L, Tang QZ. (2022). Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death. Int J Biol Sci 2022; 18(2):760-770. doi:10.7150/ijbs.65258. https://www.ijbs.com/v18p0760.htm
35. Li LY, Guan YD, Chen XS, Yang JM, Cheng Y. (2021). DNA Repair Pathways in Cancer Therapy and Resistance. Front Pharmacol. 2021 Feb 8;11:629266. doi: 10.3389/fphar.2020.629266. PMID: 33628188; PMCID: PMC7898236.
36. Li W. (2022). Measurable Residual Disease Testing in Acute Leukemia: Technology and Clinical Significance. In: Li W, editor. Leukemia [Internet]. Brisbane (AU): Exon Publications; 2022 Oct 16. Chapter 5. Available from: https://www.ncbi.nlm.nih.gov/books/NBK586210/doi: 10.36255/exon-publications-leukemia-measurable-residual-disease
37. Liang C, Qiao G, Liu Y, Tian L, Hui N, Li J, Ma Y, Li H, Zhao Q, Cao W, Liu H, Ren X. (2021). Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia. Eur J Med Chem. 2021 Aug 5;220:113451. doi: 10.1016/j.ejmech.2021.113451. Epub 2021 Apr 15. PMID: 33895500.
38. Ling-Ming Tseng; Fang Ming Chen; Shou-Tung Chen; Fiona Tsui-Fen Cheng; Tsu-Yi Chao; et al. (2024). Comparison of the Efficacy, Safety, and Quality of Life of Pegylated Liposomal Doxorubicin-Cyclophosphamide versus Epirubicin-Cyclophosphamide in Patients with Early-Stage HER2-Negative Breast Cancer: A Prospective, Randomized, Multicenter, Phase II Study. Oncol Res Treat (2024) 47 (10): 484–494. https://doi.org/10.1159/000540369

39. LiverTox. (2020). Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Carboplatin. [Updated 2020 Sep 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548565/
40. Lynne Eldridge. (2024). What is combination chemotherapy? Retrieved from Verywell Health. https://www.verywellhealth.com/what-is-combination-chemotherapy-2248995
41. Mari H. Ogino; Prasanna Tadi. (2023). Cyclophosphamide. https://www.ncbi.nlm.nih.gov/books/NBK553087/
42. Marzieh Sohrabi, Zahra Babaei, Vahid Haghpanah, Bagher Larijani, Ali Abbasi, Mohammad Mahdavi. (2022). Recent advances in gene therapy-based cancer monotherapy and synergistic bimodal therapy using upconversion nanoparticles: Structural and biological aspects. Biomedicine & Pharmacotherapy, Volume 156, 113872, ISSN 0753-3322. https://doi.org/10.1016/j.biopha.2022.113872.
43. Minerva, Bhat, Amrita, Verma, Sonali, Chander, Gresh, Jamwal, Rajeshwer Singh, Sharma, Bhawani, Bhat, Audesh, Katyal, Taruna, Kumar, Rakesh, Shah, Ruchi. (2023). Cisplatin-based combination therapy for cancer. Journal of Cancer Research and Therapeutics 19(3):p 530-536, Apr–Jun 2023. | DOI: 10.4103/jcrt.jcrt_792_22
44. Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Reza Heidari, Mohsen Chamanara, Mohammad Akbari, Naresh Poondla, Piao Yang, Sara Malih, Hamed Manoochehri, Hamid Tanzadehpanah, Hanie Mahaki, Nashmin Fayazi Hosseini, Ashkan Dirbaziyan, Sharafaldin Al-Musawi, Naser Kalhor. (2025). Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy. Biomedicine & Pharmacotherapy, Volume 184, 117858, ISSN 0753-3322. https://doi.org/10.1016/j.biopha.2025.117858.
45. Mora Lagares L, Novič M. (2022). Recent Advances on P-Glycoprotein (ABCB1) Transporter Modelling with In Silico Methods. Int J Mol Sci. 2022 Nov 26;23(23):14804. doi: 10.3390/ijms232314804. PMID: 36499131; PMCID: PMC9740644.
46. Mukherjee O, Rakshit S, Shanmugam G, Sarkar K. (2023). Role of chemotherapeutic drugs in immunomodulation of cancer. Curr Res Immunol. 2023 Aug 31;4:100068. doi: 10.1016/j.crimmu.2023.100068. PMID: 37692091; PMCID: PMC10491645.
47. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 58886963, Arsenic Trioxide. Retrieved March 27, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/58886963.
48. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 4212, Mitoxantrone. Retrieved March 27, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/Mitoxantrone.
49. National Cancer Institute. (2024). Combination of doxorubicin and trabectedin improves survival in leiomyosarcoma. Retrieved from https://www.cancer.gov/news-events/cancer-currents-blog/2024/leiomyosarcoma-yondelis-doxorubicin-improve-

survival#:~:text=The%20combination%20of%20doxorubicin%20and,uterus%2C%20abdomen%2C%20and%20pelvis.

50. National Toxicology Program. 15th Report on Carcinogens [Internet]. Research Triangle Park (NC): National Toxicology Program; 2021 Dec 21. Nitrosourea Chemotherapeutic Agents. Available from: https://www.ncbi.nlm.nih.gov/books/NBK590774/
51. Nicole G. Farha; Anup Kasi.(2024). Docetaxel. https://www.ncbi.nlm.nih.gov/books/NBK537242/#:~:text=Docetaxel%2C%20in%20combination%20with%20cisplatin,for%20castration%2Dresistant%20prostate%20cancer.
52. Nuhad K. Ibrahim. (2021). Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer. Front. Oncol. , Sec. Women's Cancer, Volume 11. https://doi.org/10.3389/fonc.2021.617874
53. Ogino MH, Tadi P. Cyclophosphamide. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553087/
54. Ok, Emmanuel. (2025). Progressing nanotechnology to improve targeted cancer treatment overcoming hurdles in its clinical implementation.
55. Olowe TG, Oyovwi MO, Nwangwa KE, Ohwin EP, Oghenetega OB. (2024). Cytotoxic Properties of Cyclophosphamide: A Focus on Its Mechanistic Impacts on Male Gonadal Functions. J Explor Res Pharmacol. 2024;9(2):106-115. doi: 10.14218/JERP.2023.00025S.
56. Orfali N, O'Donovan TR, Cahill MR, Benjamin D, Nanus DM, McKenna SL, Gudas LJ, Mongan NP. (2020). All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). Eur J Haematol. 2020 Mar;104(3):236-250. doi: 10.1111/ejh.13367. Epub 2020 Jan 13. PMID: 31811682.
57. Pamuła-Piłat, J., Tęcza, K., Kalinowska-Herok, M. et al. (2020). Genetic 3′UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients. Sci Rep10, 5736. https://doi.org/10.1038/s41598-020-62662-z
58. Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Le Cesne A, Balleyguier C, Archambaud B, Duffaud F; French Sarcoma Group. (2024). Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. N Engl J Med. 2024 Sep 5;391(9):789-799. doi: 10.1056/NEJMoa2403394. PMID: 39231341.
59. PIERRE HEUDEL, SUZETTE DELALOGE, DAMIEN PARENT, NICOLAS MADRANGES, CHRISTELLE LEVY, FLORENCE DALENC, ETIENNE BRAIN et al. (2020). Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study. Anticancer Research July 2020, 40 (7) 3905-3913; DOI: https://doi.org/10.21873/anticanres

60. Pramod Kumar, Rajesh Salve, Kavita R. Gajbhiye, Virendra Gajbhiye. (2022). Chapter 1 - An overview of stimuli-responsive nanocarriers: State of the art. Editor(s): Virendra Gajbhiye, Kavita R. Gajbhiye, Seungpyo Hong. Stimuli-Responsive Nanocarriers, Academic Press, Pages 1-27, ISBN 9780128244562. https://doi.org/10.1016/B978-0-12-824456-2.00004-7.
61. Ranasinghe R, Mathai ML, Zulli A. (2022). Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon. 2022 Sep 14;8(9):e10608. doi: 10.1016/j.heliyon.2022.e10608. PMID: 36158077; PMCID: PMC9489975.
62. Riccardo Lobefaro, Luigi Mariani, Giorgia Peverelli, Francesca Ligorio, Giovanni Fucà, Alessandro Rametta, Emma Zattarin, Rita Leporati, Daniele Presti, Beatrice Cantarelli, Catherine Depretto, Andrea Vingiani, Siranoush Manoukian, Gianfranco Scaperrotta, Giulia Bianchi V., Giuseppe Capri, Giancarlo Pruneri, Filippo de Braud, Claudio Vernieri. (2023). Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. Clinical Breast Cancer, Volume 23, Issue 3, Pages e151-e162, ISSN 1526-8209. https://doi.org/10.1016/j.clbc.2022.12.008.
63. Robert F. Ozols et al. (2023). Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 41, 4077-4083(2023). DOI:10.1200/JCO.22.02766
64. Robert Peter Gale. (2024). Combination Cancer Therapy. Retrieved from MSD Manual Consumer Version. https://www.msdmanuals.com/home/cancer/prevention-and-treatment-of-cancer/combination-cancer-therapySordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez AP, Martínez-Pérez A, Rodrigo JP, García-Pedrero JM, Gonzalez S. (2023). Chemo-Immunotherapy: A New Trend in Cancer Treatment. Cancers (Basel). 2023 May 25;15(11):2912. doi: 10.3390/cancers15112912. PMID: 37296876; PMCID: PMC10252089.
65. Synapse Patsnap. (2024). What is the mechanism of carmustine? Retrieved from https://synapse.patsnap.com/article/what-is-the-mechanism-of-carmustine?
66. Truong, N. T. H., Gargett, T., Brown, M. P., & Ebert, L. M. (2021). Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. Cancers, 13(9), 2225. https://doi.org/10.3390/cancers13092225
67. Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. (2023). Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review). Int J Oncol. 2023 Nov;63(5):119. doi: 10.3892/ijo.2023.5567. Epub 2023 Sep 1. PMID: 37654171; PMCID: PMC10546381.
68. University of Pennsylvania. (2024). Ellence (epirubicin): What to Expect, Side Effects, and More. Retrieved from https://www.breastcancer.org/drugs/ellence
69. Vaghari-Tabari M, Hassanpour P, Sadeghsoltani F, Malakoti F, Alemi F, Qujeq D, Asemi Z, Yousefi B. (2022). CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. Cell

Mol Biol Lett. 2022 Jun 17;27(1):49. doi: 10.1186/s11658-022-00348-2. PMID: 35715750; PMCID: PMC9204876.

70. Vergnenegre A, Monnet I, Ricordel C, et al. (2023). Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer 2023;178:191-7. doi: 10.21037/actr-23-53
71. Wang, H., Fan, L., Wu, X. et al. (2022). Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer. BMC Women's Health 22, 224. https://doi.org/10.1186/s12905-022-01794-y
72. Wang HY, Gong S, Li GH, Yao YZ, Zheng YS, Lu XH, Wei SH, Qin WW, Liu HB, Wang MC, Xi JY, Chen LM, Zhang M, Zhang XX, Zhang HY, Zhang CS, Wald DN, Zhu HH, Liu L, He PC. (2022). An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Blood Cancer J. 2022 Nov 21;12(11):158. doi: 10.1038/s41408-022-00753-y. PMID: 36404343; PMCID: PMC9676182.
73. Wei Wang, Wenli Li, Lili Dai, Lei Zhao, Kaixin Qu. (2022). Comparison of gemcitabine/carboplatin versus paclitaxel/cisplatin for the management of non-small cell lung cancer. Tropical Journal of Pharmaceutical Research August 2022; 21 (8): 1763-1770ISSN: 1596-5996 (print); 1596-9827 (electronic). http://dx.doi.org/10.4314/tjpr.v21i8.25
74. Wellhausen N, Agarwal S, Rommel PC, Gill SI, June CH. (2021). Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy. Curr Opin Immunol. 2022 Feb;74:76-84. doi: 10.1016/j.coi.2021.10.008. Epub 2021 Nov 16. PMID: 34798542; PMCID: PMC9337770.
75. Wu, W., Chen, J., Deng, H. et al. (2021). Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. BMC Cancer 21, 862 (2021). https://doi.l/10.1186/s12885-021-08612-y
76. Xie, S., Liu, H., Zhu, S. et al. Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα–JNK pathway. Cancer Gene Ther 31, 1486–1497 (2024). https://doi.org/10.1038/s41417-024-00818-z
77. Yan S, Na J, Liu X, Wu P. (2024). Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. Pharmaceutics. 2024 Feb 7;16(2):248. doi: 10.3390/pharmaceutics16020248. PMID: 38399302; PMCID: PMC10893104.
78. Yu C, Wang Z, Sun Z, Zhang L, Zhang W, Xu Y, Zhang JJ. (2020). Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives. J Med Chem. 25;63(22):13397-13412. doi: 10.1021/acs.jmedchem.0c00950. Epub 2020 Sep 9. PMID: 32813515.
79. Yu K, Ye F, He M, et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(9):1390–1396. doi:10.1001/jamaoncol.2020.2965

80. Zalis M, Viana Veloso GG, Aguiar PN Jr, Gimenes N, Reis MX, Matsas S, Ferreira CG. (2024). Next-generation sequencing impact on cancer care: applications, challenges, and future directions. Front Genet. 2024 Jul 9;15:1420190. doi: 10.3389/fgene.2024.1420190. PMID: 39045325; PMCID: PMC11263191.
81. Zhang C, Xu C, Gao X, Yao Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 2022 Feb 7;12(5):2115-2132. doi: 10.7150/thno.69424. PMID: 35265202; PMCID: PMC8899578.
82. Zhang L, Zhou C, Zhang S, Chen X, Liu J, Xu F, Liang W. (2002). Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Front Oncol. 2022 Aug 8;12:939249. doi: 10.3389/fonc.2022.939249. PMID: 36003765; PMCID: PMC9393416.